Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × ALK-positive NSCLC × Clear all

Phase

Phase 2 2 Phase 3 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 692 Breast Neoplasms 623 Neoplasms 581 Leukemia, Myeloid, Acute 479 Colorectal Neoplasms 451 Multiple Myeloma 442 Melanoma 423 Prostatic Neoplasms 378 Neoplasm Metastasis 367 Pancreatic Neoplasms 355 Recurrence 342 Lymphoma 340 Ovarian Neoplasms 322 Lung Neoplasms 297 Lymphoma, Non-Hodgkin 293 Leukemia 287 Glioblastoma 274 Precursor Cell Lymphoblastic Leukemia-Lymphoma 248 Stomach Neoplasms 245 Leukemia, Lymphocytic, Chronic, B-Cell 234 Carcinoma, Hepatocellular 229 Squamous Cell Carcinoma of Head and Neck 217 Lymphoma, Large B-Cell, Diffuse 215 Myelodysplastic Syndromes 212 Carcinoma, Renal Cell 208 Lymphoma, Follicular 182 Head and Neck Neoplasms 169 Brain Neoplasms 168 Triple Negative Breast Neoplasms 166 Lymphoma, Mantle-Cell 165

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07491497 2026-04-14

A Phase 1/2 Study of TRI-611 in ALK-Positive NSCLC

TRIANA Biomedicines, Inc.

Phase 1/2 Recruiting

ALK-positive NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡